Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Targeted Agent Combination in a Molecularly Defined Acute Leukemia

Distinguishing what a product is authorized to do elsewhere from what an IND investigates is a recurring discipline in annual reporting. This article prepares the regulatory operations components of an annual report for a hypothetical open IND in which an oral targeted agent is studied in combination with standard therapy in adults with a molecularly defined acute leukemia, a use not covered by any marketing authorization. The single Phase 2 study has entered 48 of 120 planned participants. The article reconciles study accounting, reports validated hypothetical safety tables with attention to treatment-specific monitoring events, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13 and explains the difference between the annual general investigational plan and the plan in the initial IND, and builds a timeline to an October 31, 2026 deadline.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24421699
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Targeted Agent Combination in a Molecularly Defined Acute Leukemia

Peivand Pirouzi, Daxaben Jigneshkumar Patel, Junyi Wu, Atchaya Ravichandran et al.
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Targeted Agent Combination in a Molecularly Defined Acute Leukemia

Peivand Pirouzi, Daxaben Jigneshkumar Patel, Junyi Wu, Atchaya Ravichandran, Nilukshan Sugumar
article en

Abstract

Distinguishing what a product is authorized to do elsewhere from what an IND investigates is a recurring discipline in annual reporting. This article prepares the regulatory operations components of an annual report for a hypothetical open IND in which an oral targeted agent is studied in combination with standard therapy in adults with a molecularly defined acute leukemia, a use not covered by any marketing authorization. The single Phase 2 study has entered 48 of 120 planned participants. The article reconciles study accounting, reports validated hypothetical safety tables with attention to treatment-specific monitoring events, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13 and explains the difference between the annual general investigational plan and the plan in the initial IND, and builds a timeline to an October 31, 2026 deadline.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for an Oral Targeted Agent Combination in a Molecularly Defined Acute Leukemia — Peivand Pirouzi, Daxaben Jigneshkumar Patel, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS